Hologic (HOLX) Stock Price
Hologic Price
Over the last 19 years Hologic grew revenue by 12.2% annually, reaching 4.10 B USD. Earnings per share have grown at 12.8% per year over the last 19 years. For Hologic, the net margin of 13.8% is down versus 33.2% a few years ago. The consensus 12-month price target for Hologic is 77.52 USD, about 2.0% above where the stock trades today. Of 23 analysts, 0 rate the stock a buy — an overall Hold consensus.
Hologic stock price
Hologic business model & stock analysis
Frequently asked questions about Hologic
The main competitors of Hologic Inc in the market include companies like Abbott Laboratories, Thermo Fisher Scientific, and Becton, Dickinson and Company.
The business model of Hologic Inc revolves around providing innovative diagnostic solutions, primarily focused on women's healthcare. Hologic develops and markets a wide range of medical devices and instruments, including imaging systems, surgical products, and molecular diagnostic assays. The company's products are designed to enable healthcare professionals to effectively screen, diagnose, and treat various conditions and diseases. Hologic is renowned for its advanced technologies in breast health, gynecology, and skeletal health, offering solutions that empower early detection and intervention. By constantly pushing the boundaries of medical technology, Hologic Inc remains committed to improving healthcare outcomes for women around the world.
Hologic Inc is primarily active in the healthcare industry, specifically in the field of diagnostic products and medical devices. With a focus on improving women's health, Hologic Inc develops and manufactures a wide range of innovative solutions. Their portfolio includes advanced imaging systems, molecular diagnostic assays, surgical instruments, and women's health screening tests. As a prominent player in the healthcare sector, Hologic Inc constantly strives to provide cutting-edge technologies and solutions to address various medical challenges.
Hologic Inc is a leading global healthcare and diagnostics company. Established in 1985, Hologic has excelled in providing innovative solutions for women's health, with a focus on early detection and treatment of breast and cervical cancers. The company's dedication to research and development has resulted in breakthrough technologies, including the introduction of the first 3D mammography system. Hologic has expanded its portfolio to include diagnostics, surgical and skeletal health, and GYN surgical products. With a strong commitment to advancing healthcare, Hologic Inc continues to make significant contributions to improving patient outcomes and quality of life.
Hologic Inc, a leading healthcare company, has achieved several significant milestones. In recent years, the company has made notable advancements in breast health solutions. They introduced the world's first 3D mammography system, which revolutionized breast cancer detection by providing clearer and more accurate images. Hologic Inc also developed the Genius™ 3D Mammography™ exam, proven to detect breast cancer at an earlier stage compared to 2D mammography alone. Furthermore, the company expanded its portfolio by acquiring Gen-Probe, a molecular diagnostics company, allowing Hologic Inc to offer a comprehensive range of diagnostic solutions. These milestones highlight Hologic Inc's commitment to innovation and improving women's healthcare outcomes.
Hologic Inc is primarily present in various countries and regions worldwide. The company has a significant presence in the United States, where it is headquartered. Additionally, Hologic Inc operates in Europe, including countries like Germany, France, Italy, and the United Kingdom. It also has a presence in Asia, particularly in countries such as China and Japan. Furthermore, Hologic Inc serves customers in Canada and Latin America, with a focus on countries like Mexico and Brazil. Overall, Hologic Inc has a global reach and aims to provide its products and services to diverse markets internationally.
Hologic Inc represents values of innovation, commitment to quality, and patient-centric approach. The corporate philosophy of Hologic Inc revolves around developing cutting-edge medical technologies to improve women's health outcomes. With a focus on providing accurate and reliable diagnostic solutions, Hologic Inc strives to empower healthcare professionals and patients alike. The company's dedication to research and development, evidence-based practices, and collaboration with healthcare experts reinforces its commitment to advancing healthcare for women globally. Hologic Inc's mission is to make a difference in people's lives through advanced healthcare solutions, making them a trusted and reliable leader in the industry.
Analysts currently set an average price target of 76.66 USD for the Hologic stock (median: 77.52 USD), implying +0.9 % versus the latest price. The consensus is based on 23 analyst ratings.
23 analysts currently rate the Hologic stock: 0 recommend buying, 20 holding and 3 selling. For 2026, analysts expect Hologic to generate revenue of 4.24 B USD and earnings per share of 4.49 USD.
Converted at the current exchange rate, the Hologic share trades at 68.04 EUR (76.01 USD).
The Hologic share (HOLX) is listed on 9 stock exchanges, including: NASDAQ (HOLX), London (0J5Q.L), SIX (Zürich) (HO1.SW), XETRA (HO1.DE), Frankfurt (HO1.F), München (HO1.MU), Düsseldorf (HO1.DU), Wien (HOLX.VI).
Hologic Inc is an international leading provider of medical technology products and solutions. The company, headquartered in Marlborough, Massachusetts, operates globally and is divided into four business segments: Diagnostics, Gynecology, Skeletal Health, and Aesthetics.
The expected revenue of Hologic is 4.24 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Hologic is 1.01 B USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Hologic is currently 16.93. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Hologic stock.
The price-to-sales ratio (P/S) of Hologic is currently 4.05. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Hologic stock.
The Eulerpool Quality Score for Hologic is 1/10.
The ISIN of Hologic is US4364401012. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Hologic is 879100. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Hologic is HOLX. The ticker symbol is used to trade Hologic shares on the stock exchange.
Hologic stock
Hologic Peer Group
Hologic Ticker
Hologic FIGI
All fundamentals and in-depth analysis of Hologic
Our stock analysis for Hologic stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hologic. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.